KYV 101
Alternative Names: Autologous anti-CD19 CAR T cell therapy - Kyverna Therapeutics; KYV-101Latest Information Update: 18 Jul 2024
At a glance
- Originator National Cancer Institute (USA); National Institutes of Health (USA)
- Developer Kyverna Therapeutics; National Institutes of Health (USA)
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Multiple sclerosis; Myasthenia gravis; Stiff-person syndrome
- Phase I/II Lupus nephritis